Merger Update :Theramex / Viatris

ANTICIPATED ACQUISITION BY THERAMEX HQ UK LIMITED OF EUROPEAN RIGHTS TO VIATRIS INC'S FEMOSTON AND DUPHASTON PRODUCTS

Invitation to comment: closes on 19 February 2024

The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this merger if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

The CMA is issuing this preliminary 'invitation to comment' to allow interested parties to submit to the CMA any initial views on the impact that the transaction could have on competition in the UK. The CMA has not yet launched its formal investigation into this transaction. This invitation to comment is the first part of the CMA's information-gathering process.

To assist it with this assessment, the CMA invites comments on the merger from any interested party.

These comments should be provided by the deadline set out above to:

Principal Case Officer: Elizabeth Coulter

E-mail: elizabeth.coulter@cma.gov.uk

Tel no: 020 3738 6230

and

Case Officer: Georgia Cummings

E-mail: georgia.cummings@cma.gov.uk

Tel no: 020 3738 6283

Your name and contact details are your personal data. In collecting, receiving, storing, accessing and using your personal data, the CMA, as controller, is processing your personal data. The CMA processes personal data in accordance with data protection law. The CMA is processing your personal data so that it can contact you again, should it need further help or information from you, in order to carry out its merger work under Part 3 of the Enterprise Act 2002. For more information about how the CMA processes personal data and your rights relating to that data, please see our Privacy Notice.